Compare Stocks: LPCN, ELOX, ALDX, and TLPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$0.92 -3.3%	$1.40	$0.86 ▼ $5.93	$57.17M	1.21	1.88 million shs	698,974 shs
ELOX Eloxx Pharmaceuticals	$13.74 -9.5%	$16.80	$8.20 ▼ $23.40	$61.27M	-1960.42	23,214 shs	31,308 shs
LPCN Lipocine	$1.72 -10.9%	$2.16	$1.72 ▼ $12.37	$15.91M	0.4	5.44 million shs	1.03 million shs
TLPH Talphera	$1.08	$1.22	$0.69 ▼ $1.57	$56.06M	0.67	163,919 shs	64,653 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-3.31%	-21.68%	-38.91%	-55.73%	-83.70%
ELOX Eloxx Pharmaceuticals	-9.49%	-11.41%	-17.08%	+16.34%	+1,248,990.91%
LPCN Lipocine	-10.88%	-16.10%	-23.56%	-28.63%	-45.57%
TLPH Talphera	0.00%	-4.42%	-11.48%	-26.03%	-18.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$0.92 -3.3%	$1.40	$0.86 ▼ $5.93	$57.17M	1.21	1.88 million shs	698,974 shs
ELOX Eloxx Pharmaceuticals	$13.74 -9.5%	$16.80	$8.20 ▼ $23.40	$61.27M	-1960.42	23,214 shs	31,308 shs
LPCN Lipocine	$1.72 -10.9%	$2.16	$1.72 ▼ $12.37	$15.91M	0.4	5.44 million shs	1.03 million shs
TLPH Talphera	$1.08	$1.22	$0.69 ▼ $1.57	$56.06M	0.67	163,919 shs	64,653 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-3.31%	-21.68%	-38.91%	-55.73%	-83.70%
ELOX Eloxx Pharmaceuticals	-9.49%	-11.41%	-17.08%	+16.34%	+1,248,990.91%
LPCN Lipocine	-10.88%	-16.10%	-23.56%	-28.63%	-45.57%
TLPH Talphera	0.00%	-4.42%	-11.48%	-26.03%	-18.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	500.24% Upside
ELOX Eloxx Pharmaceuticals	3.00	Buy	$38.33	178.99% Upside
LPCN Lipocine	2.00	Hold	$4.00	132.56% Upside
TLPH Talphera	2.25	Hold	$3.00	177.78% Upside

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ALDX, and TLPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/30/2026	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$2.00
9/29/2026	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$32.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy	$32.00
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
ELOX Eloxx Pharmaceuticals	$6.36M	8.73	N/A	N/A	($85.17) per share	-0.16
LPCN Lipocine	$1.57M	9.03	N/A	N/A	$2.61 per share	0.66
TLPH Talphera	$1K	56,058.48	N/A	N/A	$0.37 per share	2.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.27	N/A	N/A	N/A	N/A	-87.28%	-51.36%	11/11/2026 (Estimated)

Latest LPCN, ELOX, ALDX, and TLPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LPCN Lipocine	-$0.39	N/A	N/A	N/A	$0.16 million	N/A
11/4/2026	Q3 2026	ALDX Aldeyra Therapeutics	-$0.11	N/A	N/A	N/A	$2.50 million	N/A
8/13/2026	Q2 2026	TLPH Talphera	-$0.0625	-$0.06	+$0.0025	-$0.06	N/A	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
LPCN Lipocine	N/A	11.48	11.48
TLPH Talphera	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ELOX Eloxx Pharmaceuticals	2.90%
LPCN Lipocine	9.11%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
ELOX Eloxx Pharmaceuticals	25.90%
LPCN Lipocine	4.69%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
LPCN Lipocine	14	8.24 million	7.86 million	No Data
TLPH Talphera	12	51.91 million	50.09 million	Optionable

LPCN, ELOX, ALDX, and TLPH Headlines

Recent News About These Companies

Talphera (TLPH) Stock Forecast & Price Target

September 30, 2026 | investing.com

Talphera (TLPH) upgraded to buy: Here's what you should know

September 21, 2026 | msn.com

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026 | prnewswire.com

Talphera Earnings Call Highlights Nafamostat Momentum

August 23, 2026 | tipranks.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript

August 14, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...

August 13, 2026 | uk.finance.yahoo.com

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

August 13, 2026 | seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | aol.comA

Talphera Q2 2026 earnings preview

August 11, 2026 | msn.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

August 5, 2026 | prnewswire.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | finanznachrichten.de

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, ELOX, ALDX, and TLPH Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$0.92 -0.03 (-3.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.91 0.00 (-0.47%)

As of 10/9/2026 07:34 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Eloxx Pharmaceuticals NASDAQ:ELOX

$13.74 -1.44 (-9.49%)

As of 10/9/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Lipocine NASDAQ:LPCN

$1.72 -0.21 (-10.88%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.74 +0.03 (+1.45%)

As of 10/9/2026 07:58 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Talphera NASDAQ:TLPH

$1.08 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.08 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ALDX, and TLPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, ELOX, ALDX, and TLPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, ELOX, ALDX, and TLPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, ELOX, ALDX, and TLPH Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Eloxx Pharmaceuticals NASDAQ:ELOX

Lipocine NASDAQ:LPCN

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ALDX, and TLPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, ELOX, ALDX, and TLPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, ELOX, ALDX, and TLPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, ELOX, ALDX, and TLPH Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Eloxx Pharmaceuticals NASDAQ:ELOX

Lipocine NASDAQ:LPCN

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools